Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Patients with metastatic triple-negative breast cancer were treated with standard chemotherapy or the anti–Trop-2 antibody–drug conjugate sacituzumab govitecan. Patients receiving the drug conjugate had significantly longer progression-free and overall survival as well as more frequent myelotoxic ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-04, Vol.384 (16), p.1529-1541
Hauptverfasser:	Bardia, Aditya, Hurvitz, Sara A, Tolaney, Sara M, Loirat, Delphine, Punie, Kevin, Oliveira, Mafalda, Brufsky, Adam, Sardesai, Sagar D, Kalinsky, Kevin, Zelnak, Amelia B, Weaver, Robert, Traina, Tiffany, Dalenc, Florence, Aftimos, Philippe, Lynce, Filipa, Diab, Sami, Cortés, Javier, O’Shaughnessy, Joyce, Diéras, Véronique, Ferrario, Cristiano, Schmid, Peter, Carey, Lisa A, Gianni, Luca, Piccart, Martine J, Loibl, Sibylle, Goldenberg, David M, Hong, Quan, Olivo, Martin S, Itri, Loretta M, Rugo, Hope S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Aged, 80 and over Antibodies Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antigens, Neoplasm Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Brain cancer Breast cancer Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - therapeutic use Cancer therapies Cell Adhesion Molecules - antagonists & inhibitors Cell surface Chemotherapy Confidence intervals Diarrhea DNA topoisomerase Drug Resistance, Neoplasm Enrollments FDA approval Female Gemcitabine Humans Immune Checkpoint Inhibitors - therapeutic use Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Investigations Leukopenia Magnetic resonance imaging Metastases Metastasis Middle Aged Monoclonal antibodies Myelosuppression Neoplasm Recurrence, Local - drug therapy Neutropenia Progression-Free Survival Survival Analysis Targeted cancer therapy Taxanes Toxicity Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - mortality Tumor Burden Vinorelbine Writers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with metastatic triple-negative breast cancer were treated with standard chemotherapy or the anti–Trop-2 antibody–drug conjugate sacituzumab govitecan. Patients receiving the drug conjugate had significantly longer progression-free and overall survival as well as more frequent myelotoxic effects and diarrhea.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2028485